NY-ESO-1 T-cells for treating synovial sarcoma ID1286
In development [GID-TA10205] Expected publication date: TBC
Search results
2256 results
-
-
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
In development [GID-TA10251] Expected publication date: TBC
-
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
In development [GID-MT526] Expected publication date: TBC
-
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]
In development [GID-TA10633] Expected publication date: TBC
-
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus [ID1203]
In development [GID-TA10204] Expected publication date: TBC
-
Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica
In development [GID-IP2806] Expected publication date: TBC
-
Middle Meningeal Embolisation for Chronic Subdural Haematomas (CSDH)
In development [GID-IPG10215] Expected publication date: TBC
-
Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]
In development [GID-TA10616] Expected publication date: TBC
-
Irreversible electroporation for treating prostate cancer
In development [GID-IPG10213] Expected publication date: TBC
-
Endoluminal gastroplication for gastro-oesophageal reflux disease
In development [GID-IPG10225] Expected publication date: TBC
-
Ultra-radical (extensive) surgery for advanced ovarian cancer
In development [GID-IPG10226] Expected publication date: TBC
-
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain
In development [GID-MT567] Expected publication date: TBC
-
MRI-based technologies for the assessment of non-alcoholic fatty liver disease
In development [GID-DG10045] Expected publication date: 26 October 2022
-
Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538
In development [GID-TA10422] Expected publication date: TBC
-
YAG laser vitreolysis for symptomatic vitreous floaters
In development [GID-IPG10218] Expected publication date: TBC
-
Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules
In development [GID-IPG10219] Expected publication date: TBC
-
Transvenous obliteration for gastric varices
In development [GID-IPG10206] Expected publication date: TBC
-
Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease
In development [GID-IPG10209] Expected publication date: TBC
-
Percutaneous transluminal renal sympathetic denervation for resistant hypertension
In development [GID-IPG10221] Expected publication date: TBC
-
Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]
In development [GID-TA10567] Expected publication date: 22 November 2023
-
Omburtamab for treating relapsed neuroblastoma [ID1664]
In development [GID-TA10608] Expected publication date: TBC
-
Osteoporosis: assessing the risk of fragility fracture
In development [GID-NG10216] Expected publication date: 21 February 2024
-
GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)
In development [GID-MT557] Expected publication date: TBC
-
Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]
In development [GID-TAG496] Expected publication date: TBC
-
Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica
In development [GID-IP2803] Expected publication date: TBC
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]
In development [GID-TA10766] Expected publication date: TBC
-
Voclosporin with immunosuppressives for treating lupus nephritis [ID3962]
In development [GID-TA10878] Expected publication date: 25 January 2023
-
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]
In development [GID-TA10742] Expected publication date: 10 August 2022
-
Autologous auto-CD19-transduced CD3+ cells for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia in adults ID1494
In development [GID-TA10424] Expected publication date: 14 December 2022
-
Head injury: assessment and early management
In development [GID-NG10164] Expected publication date: 23 February 2023
-
Memokath-051 stent for ureteric obstruction
In development [GID-MT569] Expected publication date: 07 December 2022
-
Lower urinary tract symptoms in men: management
In development [GID-NG10300] Expected publication date: TBC
-
Sebelipase alfa for treating Wolman disease [ID3995]
In development [GID-HST10047] Expected publication date: TBC
-
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]
In development [GID-TA10714] Expected publication date: 18 May 2022
-
Vadadustat for treating anaemia in people with chronic kidney disease [ID3821]
In development [GID-TA10877] Expected publication date: TBC
-
Rimegepant for treating or preventing migraine [ID1539]
In development [GID-TA10839] Expected publication date: 01 March 2023
-
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal [TA714] Published: 14 July 2021
-
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]
Technology appraisal [TA560] Published: 20 February 2019
-
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal [TA582] Published: 24 May 2019
-
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
In development [GID-TA10764] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
In development [GID-TA10596] Expected publication date: TBC
-
Afamelanotide for treating erythropoietic protoporphyria [ID927]
In development [GID-HST10009] Expected publication date: TBC
-
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
In development [GID-TA10664] Expected publication date: TBC
-
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]
In development [GID-HST10033] Expected publication date: TBC
-
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]
In development [GID-TA10653] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]
In development [GID-TA10186] Expected publication date: TBC
-
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]
In development [GID-TA10691] Expected publication date: 13 July 2022
-
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping [ID1387]
In development [GID-TA10846] Expected publication date: TBC
-
Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]
In development [GID-TA10581] Expected publication date: TBC
-
Dapagliflozin for treating heart failure with preserved ejection fraction ID1648
In development [GID-TA10942] Expected publication date: TBC